{
    "clinical_study": {
        "@rank": "45137", 
        "arm_group": [
            {
                "arm_group_label": "Artelac Rebalance", 
                "arm_group_type": "Experimental", 
                "description": "Artelac Rebalance ophthalmic solution contains 0.15% hyaluronic acid, is unpreserved and presented in single dose units with a fill volume of 0.5 mL."
            }, 
            {
                "arm_group_label": "Vismed", 
                "arm_group_type": "Active Comparator", 
                "description": "Vismed ophthalmic solution, contains 0.18% sodium hyaluronate, is unpreserved and presented in single dose units with a fill volume of 0.3 mL."
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this investigation is to show that the performance of Artelac Rebalance eye\n      drops is non-inferior to that of Vismed eye drops in subjects with moderate to severe dry\n      eye, and to assess the safety of Artelac Rebalance after a 90-day (\u00b1 10 day) treatment\n      administered 3 to 5 times per day."
        }, 
        "brief_title": "A Study to Evaluate the Performance and Safety of Artelac Rebalance\u00ae Versus Vismed in the Management of Dry Eye", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Dry Eye", 
        "condition_browse": {
            "mesh_term": [
                "Keratoconjunctivitis Sicca", 
                "Dry Eye Syndromes"
            ]
        }, 
        "detailed_description": {
            "textblock": "Artelac Rebalance and Vismed are in compliance with European Directives (CE marked) products\n      in the European Union (EU)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who have been using tear substitutes for at least 3 months prior to\n             inclusion, and who will use preservative-free ART (Artelac\u00ae UNO CL hypromellose 0.32%\n             w/v eye drops, single dose unit) up to 6 times a day for at least 2 weeks immediately\n             prior to randomization\n\n          -  Subjects with at least 1 eye with the following signs of keratoconjunctivitis sicca\n             at 2 consecutive visits (Visit 1[Screening] and Visit 2 [Randomization])\n\n               -  Schirmer test without anesthesia of \u2264 9 mm/5min\n\n               -  Tear break-up time of \u2264 10sec (mean of 3 measurements)\n\n               -  Total ocular surface staining score \u2265 4 and \u2264 9. This assessment combines\n                  corneal fluorescein staining and nasal and temporal bulbar conjunctival\n                  lissamine green staining, each graded 0-5 according to the Oxford Scheme\n\n          -  Subjects who have a decimal visual acuity (VA) with habitual correction equal to or\n             better than 0.1 (Snellen E chart) in both eyes\n\n          -  Subjects who are receiving stable systemic treatment (unchanged for 1 month or\n             longer)\n\n        Exclusion Criteria:\n\n          -  Subjects with moderate or severe blepharitis\n\n          -  Subjects who have severe ocular dryness accompanied by 1 of the following:\n\n               -  Lid abnormality (except mild blepharitis)\n\n               -  Corneal disease\n\n               -  Ocular surface metaplasia\n\n               -  Filamentary keratitis\n\n               -  Corneal neovascularization\n\n          -  Subjects who currently wear contact lenses or have worn contact lenses within 90 days\n             prior to study start\n\n          -  Subjects who have received ocular surgery, including laser surgery, in either eye\n             within 180 days prior to study start\n\n          -  Subjects with a history of ocular trauma, non-dry eye ocular inflammation, or ocular\n             infection within 90 days prior to study start\n\n          -  Subjects with a history of ocular allergic disease or ocular herpes within\n\n             1 year prior to study start\n\n          -  Subjects with a history of any inflammatory ulcerative keratitis, recurrent corneal\n             erosion, or uveitis\n\n          -  Subjects with known hypersensitivity or contraindications to any of the ingredients\n             in the test or comparator products\n\n          -  Subjects with planned initiation of, or changes to, concomitant medication that could\n             affect dry eye within 30 days of Visit 1 (Screening) or during the study\n\n          -  Subjects who have received ocular therapy (either eye) with any ophthalmic\n             medication, except tear substitutes, within 2 weeks prior to study start\n\n          -  Subjects expected to receive ocular therapy during the study\n\n          -  Subjects treated with topical ocular steroidal or non-steroidal anti- inflammatory\n             medication within 30 days prior to study start\n\n          -  Subjects expected to receive ocular therapy with immunosuppressants (eg,\n             cyclosporine) during the study or who have used ocular immunosuppressants within 90\n             days prior to study start\n\n          -  Subjects who have received occlusion therapy with lacrimal or punctum plugs within 90\n             days prior to study start"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01791426", 
            "org_study_id": "810"
        }, 
        "intervention": [
            {
                "arm_group_label": "Artelac Rebalance", 
                "description": "Instill 1 drop of the Artelac Rebalance eye drops in each eye 3 to 5 times per day for 90(\u00b1 10) day treatment.", 
                "intervention_name": "Artelac Rebalance", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Vismed", 
                "description": "Instill 1 drop of the Vismed eye drops in each eye 3 to 5 times per day for 90(\u00b1 10) day treatment.", 
                "intervention_name": "Vismed", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 10, 2013", 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Study to Evaluate the Performance and Safety of Artelac Rebalance\u00ae Versus Vismed in the Management of Dry Eye", 
        "overall_official": {
            "affiliation": "Bausch & Lomb Incorporated", 
            "last_name": "Helmut Allmeier, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Total combined ocular surface staining grade of 0-15 combining corneal fluorescein staining score, nasal and temporal bulbar conjunctiva lissamine green staining score (each graded 0-5 on the Oxford Scheme) in the study eye.", 
            "measure": "Combined Ocular Surface Staining Score", 
            "safety_issue": "No", 
            "time_frame": "Mean change from baseline (CFB) to visit 4 (day 28)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01791426"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Mean CFB in the study eye at Visits 3, 4 and 5 in total combined ocular surface staining score.", 
                "measure": "Combined Ocular Surface Staining Score", 
                "safety_issue": "No", 
                "time_frame": "Mean CFB to visit 3 (Day 7) visit 4 (Day 28) and visit 5 (Day 90)"
            }, 
            {
                "description": "Mean CFB in the study eye in corneal fluorescein staining score at each follow-up visit", 
                "measure": "Corneal Fluorescein Staining Score", 
                "safety_issue": "No", 
                "time_frame": "Mean CFB at each follow-up visit: visit 3 (Day 7) visit 4 (Day 28) and visit 5 (Day 90)"
            }, 
            {
                "description": "Mean CFB in the study eye in nasal conjunctival lissamine green staining at each follow-up visit.", 
                "measure": "Nasal Conjunctival Lissamine Green Staining", 
                "safety_issue": "No", 
                "time_frame": "Mean CFB at each follow-up visit: visit 3 (Day 7) visit 4 (Day 28) and visit 5 (Day 90)"
            }, 
            {
                "description": "Mean CFB in the study eye in temporal conjunctival lissamine green staining at each follow-up visit", 
                "measure": "Temporal Conjunctival Lissamine Green Staining", 
                "safety_issue": "No", 
                "time_frame": "Mean CFB at each follow-up visit: visit 3 (Day 7) visit 4 (Day 28) and visit 5 (Day 90)"
            }, 
            {
                "description": "Mean CFB in the study eye in tear film break-up time (TFBUT) at each follow-up visit.", 
                "measure": "Tear Film Break-up Time", 
                "safety_issue": "No", 
                "time_frame": "Mean CFB at each follow-up visit: visit 3 (Day 7) visit 4 (Day 28) and visit 5 (Day 90)"
            }, 
            {
                "description": "Study drop sensation, as reported by subject in subject diary", 
                "measure": "Study Drop Sensation", 
                "safety_issue": "No", 
                "time_frame": "Each follow-up visit: visit 3 (Day 7) visit 4 (Day 28) and visit 5 (Day 90)"
            }
        ], 
        "source": "Bausch & Lomb Incorporated", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bausch & Lomb Incorporated", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "October 2013", 
        "why_stopped": "Adjustment of company focus due to acquision by Valeant Pharmaceuticals"
    }
}